-
1
-
-
73449143830
-
The World Health Organization (WHO) classification of lymphoid neoplasms: What's new?
-
Harris NL, Swerdlow S, Campo E, Jaffe ES, Stein H, Pileri S, et al. The World Health Organization (WHO) classification of lymphoid neoplasms: what's new? Ann Oncol 2008;19:119.
-
(2008)
Ann Oncol
, vol.19
, pp. 119
-
-
Harris, N.L.1
Swerdlow, S.2
Campo, E.3
Jaffe, E.S.4
Stein, H.5
Pileri, S.6
-
2
-
-
78049508777
-
Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
-
Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-25.
-
(2010)
Blood
, vol.116
, pp. 3418-3425
-
-
Schmitz, N.1
Trumper, L.2
Ziepert, M.3
Nickelsen, M.4
Ho, A.D.5
Metzner, B.6
-
3
-
-
84872089334
-
A systematic review and meta-analysis of front-line anthracyclinebased chemotherapy regimens for peripheral T-cell lymphoma
-
Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracyclinebased chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011;2011:623924.
-
(2011)
ISRN Hematol
, vol.2011
, pp. 623924
-
-
Abouyabis, A.N.1
Shenoy, P.J.2
Sinha, R.3
Flowers, C.R.4
Lechowicz, M.J.5
-
4
-
-
0030467763
-
Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas
-
Karakas T, Bergmann L, Stutte HJ, Jager E, Knuth A, Weidmann E, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996;24:121-9.
-
(1996)
Leuk Lymphoma
, vol.24
, pp. 121-129
-
-
Karakas, T.1
Bergmann, L.2
Stutte, H.J.3
Jager, E.4
Knuth, A.5
Weidmann, E.6
-
5
-
-
18044383718
-
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M.D. Anderson Cancer Center experience
-
Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 2005;103:2091-8.
-
(2005)
Cancer
, vol.103
, pp. 2091-2098
-
-
Escalon, M.P.1
Liu, N.S.2
Yang, Y.3
Hess, M.4
Walker, P.L.5
Smith, T.L.6
-
6
-
-
33744811464
-
Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: Single institutional study
-
Sung HJ, Kim SJ, Seo HY, Sul HR, Choi JG, Choi IK, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol 2006;134:45-53.
-
(2006)
Br J Haematol
, vol.134
, pp. 45-53
-
-
Sung, H.J.1
Kim, S.J.2
Seo, H.Y.3
Sul, H.R.4
Choi, J.G.5
Choi, I.K.6
-
7
-
-
47049084821
-
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project
-
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111: 5496-504.
-
(2008)
Blood
, vol.111
, pp. 5496-5504
-
-
Savage, K.J.1
Harris, N.L.2
Vose, J.M.3
Ullrich, F.4
Jaffe, E.S.5
Connors, J.M.6
-
8
-
-
51649091675
-
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
-
Vose J, Armitage J, Weisenburger DInternational TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26: 4124-30.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4124-4130
-
-
Vose, J.1
Armitage, J.2
Tclp, W.D.3
-
9
-
-
78851470560
-
Pathology and biology of peripheral T-cell lymphomas
-
de Leval L, Gaulard P. Pathology and biology of peripheral T-cell lymphomas. Histopathology 2011;58:49-68.
-
(2011)
Histopathology
, vol.58
, pp. 49-68
-
-
De Leval, L.1
Gaulard, P.2
-
10
-
-
53249123632
-
-
Lyon, France: IARC Press
-
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haemaopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
-
(2008)
WHO Classification of Tumours of Haemaopoietic and Lymphoid Tissues. 4th Ed.
-
-
Swerdlow, S.H.1
Campo, E.2
Harris, N.L.3
Jaffe, E.S.4
Pileri, S.A.5
Stein, H.6
-
11
-
-
0033963698
-
Chromosome abnormalities in peripheral T-cell lymphoma
-
Lepretre S, Buchonnet G, Stamatoullas A, Lenain P, Duval C, d'Anjou J, et al. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 2000;117:71-9.
-
(2000)
Cancer Genet Cytogenet
, vol.117
, pp. 71-79
-
-
Lepretre, S.1
Buchonnet, G.2
Stamatoullas, A.3
Lenain, P.4
Duval, C.5
D'Anjou, J.6
-
12
-
-
0028047151
-
Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas
-
Schlegelberger B, Himmler A, Godde E, Grote W, Feller AC, Lennert K. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas. Blood 1994; 83:505-11.
-
(1994)
Blood
, vol.83
, pp. 505-511
-
-
Schlegelberger, B.1
Himmler, A.2
Godde, E.3
Grote, W.4
Feller, A.C.5
Lennert, K.6
-
13
-
-
42449134368
-
Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma
-
Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol 2008; 141:461-9.
-
(2008)
Br J Haematol
, vol.141
, pp. 461-469
-
-
Nelson, M.1
Horsman, D.E.2
Weisenburger, D.D.3
Gascoyne, R.D.4
Dave, B.J.5
Loberiza, F.R.6
-
14
-
-
1942501550
-
Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations
-
Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch-Klupp I, Sonnen R, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004;164: 1837-48.
-
(2004)
Am J Pathol
, vol.164
, pp. 1837-1848
-
-
Zettl, A.1
Rudiger, T.2
Konrad, M.A.3
Chott, A.4
Simonitsch-Klupp, I.5
Sonnen, R.6
-
15
-
-
33751081530
-
Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrixbased CGH approach
-
Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrixbased CGH approach. Genes Chromosomes Cancer 2007;46: 37-44.
-
(2007)
Genes Chromosomes Cancer
, vol.46
, pp. 37-44
-
-
Thorns, C.1
Bastian, B.2
Pinkel, D.3
Roydasgupta, R.4
Fridlyand, J.5
Merz, H.6
-
16
-
-
39149093028
-
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma
-
Nagel S, Leich E, Quentmeier H, Meyer C, Kaufmann M, Drexler HG, et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 2008;22:387-92.
-
(2008)
Leukemia
, vol.22
, pp. 387-392
-
-
Nagel, S.1
Leich, E.2
Quentmeier, H.3
Meyer, C.4
Kaufmann, M.5
Drexler, H.G.6
-
17
-
-
38949116321
-
Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas
-
Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008;140:516-26.
-
(2008)
Br J Haematol
, vol.140
, pp. 516-526
-
-
Salaverria, I.1
Bea, S.2
Lopez-Guillermo, A.3
Lespinet, V.4
Pinyol, M.5
Burkhardt, B.6
-
18
-
-
36348982897
-
Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
-
Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007; 67:10703-10.
-
(2007)
Cancer Res
, vol.67
, pp. 10703-10710
-
-
Piccaluga, P.P.1
Agostinelli, C.2
Califano, A.3
Carbone, A.4
Fantoni, L.5
Ferrari, S.6
-
19
-
-
34249652415
-
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells
-
de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109: 4952-63.
-
(2007)
Blood
, vol.109
, pp. 4952-4963
-
-
De Leval, L.1
Rickman, D.S.2
Thielen, C.3
Reynies, A.4
Huang, Y.L.5
Delsol, G.6
-
20
-
-
77649206608
-
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T- cell lymphoma
-
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T- cell lymphoma. Blood 2010;115:1026-36.
-
(2010)
Blood
, vol.115
, pp. 1026-1036
-
-
Iqbal, J.1
Weisenburger, D.D.2
Greiner, T.C.3
Vose, J.M.4
McKeithan, T.5
Kucuk, C.6
-
21
-
-
4143126609
-
Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes
-
Martinez-Delgado B, Melendez B, Cuadros M, Alvarez J, Castrillo JM, Ruiz De La Parte A, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 2004;10: 4971-82.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4971-4982
-
-
Martinez-Delgado, B.1
Melendez, B.2
Cuadros, M.3
Alvarez, J.4
Castrillo, J.M.5
De La Ruiz Parte, A.6
-
22
-
-
33644834348
-
Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas
-
Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006;25: 1560-70.
-
(2006)
Oncogene
, vol.25
, pp. 1560-1570
-
-
Ballester, B.1
Ramuz, O.2
Gisselbrecht, C.3
Doucet, G.4
Loi, L.5
Loriod, B.6
-
23
-
-
34548254943
-
Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas
-
Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007;25:3321-9.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3321-3329
-
-
Cuadros, M.1
Dave, S.S.2
Jaffe, E.S.3
Honrado, E.4
Milne, R.5
Alves, J.6
-
24
-
-
33847402218
-
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
-
Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007;117:823-34.
-
(2007)
J Clin Invest
, vol.117
, pp. 823-834
-
-
Piccaluga, P.P.1
Agostinelli, C.2
Califano, A.3
Rossi, M.4
Basso, K.5
Zupo, S.6
-
25
-
-
79953124083
-
Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral Tcell Lymphoma Project
-
Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral Tcell Lymphoma Project. Blood 2011;117:3402-8.
-
(2011)
Blood
, vol.117
, pp. 3402-3408
-
-
Weisenburger, D.D.1
Savage, K.J.2
Harris, N.L.3
Gascoyne, R.D.4
Jaffe, E.S.5
MacLennan, K.A.6
-
26
-
-
31444450512
-
Novel t(5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma
-
Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006;20:313-8.
-
(2006)
Leukemia
, vol.20
, pp. 313-318
-
-
Streubel, B.1
Vinatzer, U.2
Willheim, M.3
Raderer, M.4
Chott, A.5
-
27
-
-
77952295698
-
The fusion kinase ITK -SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma
-
Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, Kremer M, et al. The fusion kinase ITK -SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 2010;207:1031-44.
-
(2010)
J Exp Med
, vol.207
, pp. 1031-1044
-
-
Pechloff, K.1
Holch, J.2
Ferch, U.3
Schweneker, M.4
Brunner, K.5
Kremer, M.6
-
28
-
-
77955368298
-
The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease
-
Dierks C, Adrian F, Fisch P, Ma H, Maurer H, Herchenbach D, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 2010;70: 6193-204.
-
(2010)
Cancer Res
, vol.70
, pp. 6193-6204
-
-
Dierks, C.1
Adrian, F.2
Fisch, P.3
Ma, H.4
Maurer, H.5
Herchenbach, D.6
-
29
-
-
45149121371
-
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas
-
Feldman AL, Sun DX, Law ME, Novak AJ, Attygalle AD, Thorland EC, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008;22:1139-43.
-
(2008)
Leukemia
, vol.22
, pp. 1139-1143
-
-
Feldman, A.L.1
Sun, D.X.2
Law, M.E.3
Novak, A.J.4
Attygalle, A.D.5
Thorland, E.C.6
-
30
-
-
84866363110
-
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral Tcell lymphomas
-
Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral Tcell lymphomas. Blood 2012;120:2280-9.
-
(2012)
Blood
, vol.120
, pp. 2280-2289
-
-
Vasmatzis, G.1
Johnson, S.H.2
Knudson, R.A.3
Ketterling, R.P.4
Braggio, E.5
Fonseca, R.6
-
31
-
-
84895809383
-
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma
-
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46:171-5.
-
(2014)
Nat Genet
, vol.46
, pp. 171-175
-
-
Sakata-Yanagimoto, M.1
Enami, T.2
Yoshida, K.3
Shiraishi, Y.4
Ishii, R.5
Miyake, Y.6
-
32
-
-
84895829862
-
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
-
Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014;46:166-70.
-
(2014)
Nat Genet
, vol.46
, pp. 166-170
-
-
Palomero, T.1
Couronne, L.2
Khiabanian, H.3
Kim, M.Y.4
Ambesi-Impiombato, A.5
Perez-Garcia, A.6
-
33
-
-
84897381595
-
A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma
-
Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46:371-5.
-
(2014)
Nat Genet
, vol.46
, pp. 371-375
-
-
Yoo, H.Y.1
Sung, M.K.2
Lee, S.H.3
Kim, S.4
Lee, H.5
Park, S.6
-
34
-
-
76449086166
-
Advances in the understanding and management of angioimmunoblastic T-cell lymphoma
-
de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010;148:673-89.
-
(2010)
Br J Haematol
, vol.148
, pp. 673-689
-
-
De Leval, L.1
Gisselbrecht, C.2
Gaulard, P.3
-
35
-
-
58749111095
-
Peripheral T-cell lymphoma with follicular T-cell markers
-
Rodriguez-Pinilla SM, Atienza L, Murillo C, Perez-Rodriguez A, Montes- Moreno S, Roncador G, et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol 2008;32:1787-99.
-
(2008)
Am J Surg Pathol
, vol.32
, pp. 1787-1799
-
-
Rodriguez-Pinilla, S.M.1
Atienza, L.2
Murillo, C.3
Perez-Rodriguez, A.4
Montes- Moreno, S.5
Roncador, G.6
-
36
-
-
79960062301
-
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis
-
Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner- Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38.
-
(2011)
Cancer Cell
, vol.20
, pp. 25-38
-
-
Quivoron, C.1
Couronne, L.2
Della Valle, V.3
Lopez, C.K.4
Plo, I.5
Wagner- Ballon, O.6
-
37
-
-
84865197558
-
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
-
Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012;120:1466-9.
-
(2012)
Blood
, vol.120
, pp. 1466-1469
-
-
Lemonnier, F.1
Couronne, L.2
Parrens, M.3
Jais, J.P.4
Travert, M.5
Lamant, L.6
-
38
-
-
84855718050
-
TET2 and DNMT3A mutations in human T-cell lymphoma
-
Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012;366:95-6.
-
(2012)
N Engl J Med
, vol.366
, pp. 95-96
-
-
Couronne, L.1
Bastard, C.2
Bernard, O.A.3
-
39
-
-
84896617557
-
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
-
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014;123:1293-6.
-
(2014)
Blood
, vol.123
, pp. 1293-1296
-
-
Odejide, O.1
Weigert, O.2
Lane, A.A.3
Toscano, D.4
Lunning, M.A.5
Kopp, N.6
-
40
-
-
84857575341
-
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
-
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012;119:1901-3.
-
(2012)
Blood
, vol.119
, pp. 1901-1903
-
-
Cairns, R.A.1
Iqbal, J.2
Lemonnier, F.3
Kucuk, C.4
De Leval, L.5
Jais, J.P.6
-
41
-
-
34948834758
-
Pathobiology of ALK+ anaplastic large-cell lymphoma
-
Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007;110:2259-67.
-
(2007)
Blood
, vol.110
, pp. 2259-2267
-
-
Amin, H.M.1
Lai, R.2
-
42
-
-
0034554843
-
CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features
-
Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95.
-
(2000)
Blood
, vol.96
, pp. 3681-3695
-
-
Stein, H.1
Foss, H.D.2
Durkop, H.3
Marafioti, T.4
Delsol, G.5
Pulford, K.6
-
43
-
-
0036566557
-
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma
-
Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002;99:3398-403.
-
(2002)
Blood
, vol.99
, pp. 3398-3403
-
-
Jundt, F.1
Anagnostopoulos, I.2
Forster, R.3
Mathas, S.4
Stein, H.5
Dorken, B.6
-
44
-
-
78650336216
-
C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC
-
Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H. C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: identification of a novel fusion gene ALO17/C-MYC.AmJ Hematol 2011;86:75-8.
-
(2011)
AmJ Hematol
, vol.86
, pp. 75-78
-
-
Moritake, H.1
Shimonodan, H.2
Marutsuka, K.3
Kamimura, S.4
Kojima, H.5
Nunoi, H.6
-
45
-
-
0036731862
-
The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas
-
Raetz EA, Perkins SL, Carlson MA, Schooler KP, Carroll WL, Virshup DM. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. Am J Pathol 2002;161:875-83.
-
(2002)
Am J Pathol
, vol.161
, pp. 875-883
-
-
Raetz, E.A.1
Perkins, S.L.2
Carlson, M.A.3
Schooler, K.P.4
Carroll, W.L.5
Virshup, D.M.6
-
46
-
-
39749126476
-
Analysis of gene expression profile of TPM3- ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma
-
Bohling SD, Jenson SD, Crockett DK, Schumacher JA, Elenitoba- Johnson KS, Lim MS. Analysis of gene expression profile of TPM3- ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma. Leuk Res 2008;32:383-93.
-
(2008)
Leuk Res
, vol.32
, pp. 383-393
-
-
Bohling, S.D.1
Jenson, S.D.2
Crockett, D.K.3
Schumacher, J.A.4
Elenitoba- Johnson, K.S.5
Lim, M.S.6
-
47
-
-
77957984238
-
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma
-
Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A 2010;107: 16228-33.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 16228-16233
-
-
Merkel, O.1
Hamacher, F.2
Laimer, D.3
Sifft, E.4
Trajanoski, Z.5
Scheideler, M.6
-
48
-
-
20144385625
-
Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas
-
Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 2005;36: 494-504.
-
(2005)
Hum Pathol
, vol.36
, pp. 494-504
-
-
Thompson, M.A.1
Stumph, J.2
Henrickson, S.E.3
Rosenwald, A.4
Wang, Q.5
Olson, S.6
-
49
-
-
33847406330
-
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK +subtypes
-
Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK +subtypes. Blood 2007;109: 2156-64.
-
(2007)
Blood
, vol.109
, pp. 2156-2164
-
-
Lamant, L.1
De Reynies, A.2
Duplantier, M.M.3
Rickman, D.S.4
Sabourdy, F.5
Giuriato, S.6
-
50
-
-
84891544479
-
PRDM1/ BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma
-
Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F, et al. PRDM1/ BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood 2013;122:2683-93.
-
(2013)
Blood
, vol.122
, pp. 2683-2693
-
-
Boi, M.1
Rinaldi, A.2
Kwee, I.3
Bonetti, P.4
Todaro, M.5
Tabbo, F.6
-
51
-
-
0344430110
-
Peripheral T-cell lymphomas expressing CD30 and CD15
-
Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003;27:1513-22.
-
(2003)
Am J Surg Pathol
, vol.27
, pp. 1513-1522
-
-
Barry, T.S.1
Jaffe, E.S.2
Sorbara, L.3
Raffeld, M.4
Pittaluga, S.5
-
52
-
-
77951906200
-
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral Tcell neoplasms
-
Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral Tcell neoplasms. J Clin Oncol 2010;28:1583-90.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1583-1590
-
-
Piva, R.1
Agnelli, L.2
Pellegrino, E.3
Todoerti, K.4
Grosso, V.5
Tamagno, I.6
-
53
-
-
84865176067
-
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma
-
Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012;120:1274-81.
-
(2012)
Blood
, vol.120
, pp. 1274-1281
-
-
Agnelli, L.1
Mereu, E.2
Pellegrino, E.3
Limongi, T.4
Kwee, I.5
Bergaggio, E.6
-
54
-
-
84881010867
-
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
-
Bisig B, de Reynies A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica 2013; 98:1250-8.
-
(2013)
Haematologica
, vol.98
, pp. 1250-1258
-
-
Bisig, B.1
De Reynies, A.2
Bonnet, C.3
Sujobert, P.4
Rickman, D.S.5
Marafioti, T.6
-
55
-
-
84907379195
-
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
-
Parilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124:1473-80.
-
(2014)
Blood
, vol.124
, pp. 1473-1480
-
-
Parilla Castellar, E.R.1
Jaffe, E.S.2
Said, J.W.3
Swerdlow, S.H.4
Ketterling, R.P.5
Knudson, R.A.6
-
56
-
-
84872060324
-
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non- Hodgkin lymphoma: Southwest Oncology Group Study S0350
-
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non- Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013;119: 371-9.
-
(2013)
Cancer
, vol.119
, pp. 371-379
-
-
Mahadevan, D.1
Unger, J.M.2
Spier, C.M.3
Persky, D.O.4
Young, F.5
LeBlanc, M.6
-
57
-
-
84901988214
-
The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
-
Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J 2014;4: e214.
-
(2014)
Blood Cancer J
, vol.4
, pp. e214
-
-
Briski, R.1
Feldman, A.L.2
Bailey, N.G.3
Lim, M.S.4
Ristow, K.5
Habermann, T.M.6
-
58
-
-
81755172136
-
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T- cell lymphoma, nasal type: The NK-Cell Tumor Study Group study
-
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T- cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-6.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4410-4416
-
-
Yamaguchi, M.1
Kwong, Y.L.2
Kim, W.S.3
Maeda, Y.4
Hashimoto, C.5
Suh, C.6
-
59
-
-
79951483189
-
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
-
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117: 1834-9.
-
(2011)
Blood
, vol.117
, pp. 1834-1839
-
-
Jaccard, A.1
Gachard, N.2
Marin, B.3
Rogez, S.4
Audrain, M.5
Suarez, F.6
-
60
-
-
0035074460
-
CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?
-
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001;12:349-52.
-
(2001)
Ann Oncol
, vol.12
, pp. 349-352
-
-
Kim, W.S.1
Song, S.Y.2
Ahn, Y.C.3
Ko, Y.H.4
Baek, C.H.5
Kim, D.Y.6
-
61
-
-
68449086271
-
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: Extranodal natural killer/T-cell lymphoma
-
Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim do H, et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 2009;50:757-63.
-
(2009)
Leuk Lymphoma
, vol.50
, pp. 757-763
-
-
Kim, H.S.1
Kim, K.H.2
Kim, K.H.3
Chang, M.H.4
Ji, S.H.5
Lim Do, H.6
-
62
-
-
77952578954
-
Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation
-
Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664-70.
-
(2010)
Blood
, vol.115
, pp. 3664-3670
-
-
Sieniawski, M.1
Angamuthu, N.2
Boyd, K.3
Chasty, R.4
Davies, J.5
Forsyth, P.6
-
63
-
-
84908319588
-
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
-
Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28:1885-91.
-
(2014)
Leukemia
, vol.28
, pp. 1885-1891
-
-
Corradini, P.1
Vitolo, U.2
Rambaldi, A.3
Miceli, R.4
Patriarca, F.5
Gallamini, A.6
-
64
-
-
33747596427
-
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation
-
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20: 1533-8.
-
(2006)
Leukemia
, vol.20
, pp. 1533-1538
-
-
Corradini, P.1
Tarella, C.2
Zallio, F.3
Dodero, A.4
Zanni, M.5
Valagussa, P.6
-
65
-
-
84865712593
-
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
-
d'Amore F, Relander T,Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30: 3093-9.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3093-3099
-
-
D'Amore, F.1
Relander, T.2
Lauritzsen, G.F.3
Jantunen, E.4
Hagberg, H.5
Anderson, H.6
-
66
-
-
84925284213
-
Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/ T-cell lymphoma patients
-
Aug 2. [Epub ahead of print]
-
Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, et al. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/ T-cell lymphoma patients. Ann Hematol 2014 Aug 2. [Epub ahead of print].
-
(2014)
Ann Hematol
-
-
Kim, S.J.1
Park, S.2
Kang, E.S.3
Choi, J.Y.4
Lim, D.H.5
Ko, Y.H.6
-
67
-
-
43049095718
-
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
-
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19: 958-63.
-
(2008)
Ann Oncol
, vol.19
, pp. 958-963
-
-
Mercadal, S.1
Briones, J.2
Xicoy, B.3
Pedro, C.4
Escoda, L.5
Estany, C.6
-
68
-
-
70849099193
-
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: A comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
-
Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009;20:1977-84.
-
(2009)
Ann Oncol
, vol.20
, pp. 1977-1984
-
-
Nickelsen, M.1
Ziepert, M.2
Zeynalova, S.3
Glass, B.4
Metzner, B.5
Leithaeuser, M.6
-
69
-
-
34347266576
-
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group
-
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79:32-8.
-
(2007)
Eur J Haematol
, vol.79
, pp. 32-38
-
-
Rodriguez, J.1
Conde, E.2
Gutierrez, A.3
Arranz, R.4
Leon, A.5
Marin, J.6
-
70
-
-
58149347800
-
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study
-
Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106-13.
-
(2009)
J Clin Oncol
, vol.27
, pp. 106-113
-
-
Reimer, P.1
Rudiger, T.2
Geissinger, E.3
Weissinger, F.4
Nerl, C.5
Schmitz, N.6
-
71
-
-
2942677243
-
Graft-versus-lymphoma effect in relapsed peripheral T-cell non- Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells
-
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non- Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172-6.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2172-2176
-
-
Corradini, P.1
Dodero, A.2
Zallio, F.3
Caracciolo, D.4
Casini, M.5
Bregni, M.6
-
72
-
-
84873311535
-
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience
-
Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13:8-14.
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, pp. 8-14
-
-
Voss, M.H.1
Lunning, M.A.2
Maragulia, J.C.3
Papadopoulos, E.B.4
Goldberg, J.5
Zelenetz, A.D.6
-
73
-
-
70349310325
-
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
-
O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357-64.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4357-4364
-
-
O'Connor, O.A.1
Horwitz, S.2
Hamlin, P.3
Portlock, C.4
Moskowitz, C.H.5
Sarasohn, D.6
-
74
-
-
34848829782
-
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
-
O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139: 425-8.
-
(2007)
Br J Haematol
, vol.139
, pp. 425-428
-
-
O'Connor, O.A.1
Hamlin, P.A.2
Portlock, C.3
Moskowitz, C.H.4
Noy, A.5
Straus, D.J.6
-
75
-
-
79952749741
-
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study
-
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-9.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1182-1189
-
-
O'Connor, O.A.1
Pro, B.2
Pinter-Brown, L.3
Bartlett, N.4
Popplewell, L.5
Coiffier, B.6
-
76
-
-
67651202352
-
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non- Hodgkin's or Hodgkin's lymphoma
-
Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non- Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2009;86: 190-6.
-
(2009)
Clin Pharmacol Ther
, vol.86
, pp. 190-196
-
-
Mould, D.R.1
Sweeney, K.2
Duffull, S.B.3
Neylon, E.4
Hamlin, P.5
Horwitz, S.6
-
77
-
-
84886099830
-
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer
-
Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013;14: 765-80.
-
(2013)
Nat Rev Genet
, vol.14
, pp. 765-780
-
-
Plass, C.1
Pfister, S.M.2
Lindroth, A.M.3
Bogatyrova, O.4
Claus, R.5
Lichter, P.6
-
78
-
-
84875496294
-
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible
-
Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013;339: 1621-5.
-
(2013)
Science
, vol.339
, pp. 1621-1625
-
-
Losman, J.A.1
Looper, R.E.2
Koivunen, P.3
Lee, S.4
Schneider, R.K.5
McMahon, C.6
-
79
-
-
84876889621
-
What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer
-
Losman JA, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Gene Dev 2013; 27:836-52.
-
(2013)
Gene Dev
, vol.27
, pp. 836-852
-
-
Losman, J.A.1
Kaelin, W.G.2
-
80
-
-
84877632013
-
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
-
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340: 626-30.
-
(2013)
Science
, vol.340
, pp. 626-630
-
-
Rohle, D.1
Popovici-Muller, J.2
Palaskas, N.3
Turcan, S.4
Grommes, C.5
Campos, C.6
-
81
-
-
84901020086
-
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1
-
Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA, et al. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 2014;289:13717-25.
-
(2014)
J Biol Chem
, vol.289
, pp. 13717-13725
-
-
Davis, M.I.1
Gross, S.2
Shen, M.3
Straley, K.S.4
Pragani, R.5
Lea, W.A.6
-
82
-
-
33845996135
-
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
-
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31-9.
-
(2007)
Blood
, vol.109
, pp. 31-39
-
-
Duvic, M.1
Talpur, R.2
Ni, X.3
Zhang, C.4
Hazarika, P.5
Kelly, C.6
-
83
-
-
34547683194
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
-
Olsen E, Kim Y, Kuzel T, Pacheco T, Foss F, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-15.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3109-3115
-
-
Olsen, E.1
Kim, Y.2
Kuzel, T.3
Pacheco, T.4
Foss, F.5
Parker, S.6
-
84
-
-
73949149251
-
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
-
Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-7.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5410-5417
-
-
Piekarz, R.1
Frye, R.2
Turner, M.3
Wright, J.4
Allen, S.5
Kirschbaum, M.6
-
85
-
-
79952977561
-
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
-
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827-34.
-
(2011)
Blood
, vol.117
, pp. 5827-5834
-
-
Piekarz, R.L.1
Frye, R.2
Prince, H.M.3
Kirschbaum, M.H.4
Zain, J.5
Allen, S.L.6
-
86
-
-
84857522968
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
-
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6.
-
(2012)
J Clin Oncol
, vol.30
, pp. 631-636
-
-
Coiffier, B.1
Pro, B.2
Prince, H.M.3
Foss, F.4
Sokol, L.5
Greenwood, M.6
-
87
-
-
84884558230
-
Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/RPTCL): Results from the BELIEF trial
-
O'Connor OA, Masszi T, Savage KJ, Pinter-Brown LC, Foss FM, Popplewell L, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/RPTCL): results from the BELIEF trial. J Clin Oncol 2013;31(suppl 1145; abstr 8507).
-
(2013)
J Clin Oncol
, vol.31
-
-
O'Connor, O.A.1
Masszi, T.2
Savage, K.J.3
Pinter-Brown, L.C.4
Foss, F.M.5
Popplewell, L.6
-
88
-
-
84911967733
-
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin
-
May 28. [Epub ahead of print]
-
Luchenko VL, Litman T, Chakraborty AR, Heffner A, Devor C, Wilkerson J, et al. Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin. Mol Oncol 2014 May 28. [Epub ahead of print].
-
(2014)
Mol Oncol
-
-
Luchenko, V.L.1
Litman, T.2
Chakraborty, A.R.3
Heffner, A.4
Devor, C.5
Wilkerson, J.6
-
89
-
-
71949117093
-
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1
-
Chen S, Dai Y, Pei X, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 2009;29:6149-69.
-
(2009)
Mol Cell Biol
, vol.29
, pp. 6149-6169
-
-
Chen, S.1
Dai, Y.2
Pei, X.3
Grant, S.4
-
90
-
-
80052840489
-
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors
-
Jóna A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM, et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011;39:1007-17.
-
(2011)
Exp Hematol
, vol.39
, pp. 1007-1017
-
-
Jóna, A.1
Khaskhely, N.2
Buglio, D.3
Shafer, J.A.4
Derenzini, E.5
Bollard, C.M.6
-
91
-
-
79956125729
-
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737
-
Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM, et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 2011;71: 3603-15.
-
(2011)
Cancer Res
, vol.71
, pp. 3603-3615
-
-
Wiegmans, A.P.1
Alsop, A.E.2
Bots, M.3
Cluse, L.A.4
Williams, S.P.5
Banks, K.M.6
-
92
-
-
84883565304
-
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors
-
Ierano C, Chakraborty AR, Nicolae A, Bahr JC, Zhan Z, Pittaluga S, et al. Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle 2013;12: 2829-38.
-
(2013)
Cell Cycle
, vol.12
, pp. 2829-2838
-
-
Ierano, C.1
Chakraborty, A.R.2
Nicolae, A.3
Bahr, J.C.4
Zhan, Z.5
Pittaluga, S.6
-
93
-
-
29044446185
-
Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitorinduced cell death
-
Ozaki K, Minoda A, Kishikawa F, Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitorinduced cell death. Biochem Biophys Res Commun 2006;339: 1171-7.
-
(2006)
Biochem Biophys Res Commun
, vol.339
, pp. 1171-1177
-
-
Ozaki, K.1
Minoda, A.2
Kishikawa, F.3
Kohno, M.4
-
94
-
-
70350494322
-
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
-
Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114: 2733-43.
-
(2009)
Blood
, vol.114
, pp. 2733-2743
-
-
Fiskus, W.1
Wang, Y.2
Sreekumar, A.3
Buckley, K.M.4
Shi, H.5
Jillella, A.6
-
95
-
-
84899893338
-
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells
-
Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014;135:1142-54.
-
(2014)
Mol Cancer Ther
, vol.135
, pp. 1142-1154
-
-
Fiskus, W.1
Sharma, S.2
Qi, J.3
Valenta, J.A.4
Schaub, L.J.5
Shah, B.6
-
96
-
-
84922288173
-
Highly effective combination of LSD1 (KDM1A) antagonist and panhistone deacetylase inhibitor against human AML cells
-
Apr 4. [Epub ahead of print]
-
Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and panhistone deacetylase inhibitor against human AML cells. Leukemia 2014 Apr 4. [Epub ahead of print].
-
(2014)
Leukemia
-
-
Fiskus, W.1
Sharma, S.2
Shah, B.3
Portier, B.P.4
Devaraj, S.G.5
Liu, K.6
-
97
-
-
84899454045
-
The combination of hypomethylating agents and histone deacetylase inhibitors (HDACi) are synergistically cytotoxic and reverse the malignant phenotype in preclinical models of T-cell lymphoma
-
O'Connor O, Marchi E, Zullo K, Scotto L, Amengual JE, Fuligni F, et al. The combination of hypomethylating agents and histone deacetylase inhibitors (HDACi) are synergistically cytotoxic and reverse the malignant phenotype in preclinical models of T-cell lymphoma. Blood 2013;122:646.
-
(2013)
Blood
, vol.122
, pp. 646
-
-
O'Connor, O.1
Marchi, E.2
Zullo, K.3
Scotto, L.4
Amengual, J.E.5
Fuligni, F.6
-
98
-
-
84863678237
-
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
-
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2190-2196
-
-
Pro, B.1
Advani, R.2
Brice, P.3
Bartlett, N.L.4
Rosenblatt, J.D.5
Illidge, T.6
-
99
-
-
84901457807
-
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
-
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123: 3095-100.
-
(2014)
Blood
, vol.123
, pp. 3095-3100
-
-
Horwitz, S.M.1
Advani, R.H.2
Bartlett, N.L.3
Jacobsen, E.D.4
Sharman, J.P.5
O'Connor, O.A.6
-
100
-
-
84892916318
-
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non- Hodgkin lymphomas
-
Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non- Hodgkin lymphomas. J Clin Oncol 2014;32:44-50.
-
(2014)
J Clin Oncol
, vol.32
, pp. 44-50
-
-
Friedberg, J.W.1
Mahadevan, D.2
Cebula, E.3
Persky, D.4
Lossos, I.5
Agarwal, A.B.6
-
101
-
-
84910079733
-
U.S. intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patientswith peripheral T-cell lymphoma (PTCL; NCT01466881)
-
Barr PM, Li H, Spier CM, Mahadevan D, Friedberg JW, LeBlanc ML, et al. U.S. intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patientswith peripheral T-cell lymphoma (PTCL; NCT01466881). J Clin Oncol 32:5s, 2014 (suppl; abstr 8523).
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Barr, P.M.1
Li, H.2
Spier, C.M.3
Mahadevan, D.4
Friedberg, J.W.5
LeBlanc, M.L.6
-
102
-
-
77957333557
-
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
-
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010;151:159-66.
-
(2010)
Br J Haematol
, vol.151
, pp. 159-166
-
-
Simon, A.1
Peoch, M.2
Casassus, P.3
Deconinck, E.4
Colombat, P.5
Desablens, B.6
-
103
-
-
34948824913
-
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
-
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-23.
-
(2007)
Blood
, vol.110
, pp. 2316-2323
-
-
Gallamini, A.1
Zaja, F.2
Patti, C.3
Billio, A.4
Specchia, M.R.5
Tucci, A.6
-
104
-
-
84868193440
-
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial
-
Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012;48:3223-31.
-
(2012)
Eur J Cancer
, vol.48
, pp. 3223-3231
-
-
Kim, S.J.1
Yoon, D.H.2
Kang, H.J.3
Kim, J.S.4
Park, S.K.5
Kim, H.J.6
-
105
-
-
84879338660
-
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: The CONCEPT study
-
Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lmphoma 2013;54:1373-9.
-
(2013)
Leuk Lmphoma
, vol.54
, pp. 1373-1379
-
-
Foss, F.M.1
Sjak-Shie, N.2
Goy, A.3
Jacobsen, E.4
Advani, R.5
Smith, M.R.6
-
106
-
-
84871758096
-
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial
-
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013;31:104-10.
-
(2013)
J Clin Oncol
, vol.31
, pp. 104-110
-
-
Damaj, G.1
Gressin, R.2
Bouabdallah, K.3
Cartron, G.4
Choufi, B.5
Gyan, E.6
-
107
-
-
77953747413
-
Tools and landscapes of epigenetics
-
Tarakhovsky A. Tools and landscapes of epigenetics. Nat Immunol 2010;11:565-8.
-
(2010)
Nat Immunol
, vol.11
, pp. 565-568
-
-
Tarakhovsky, A.1
-
108
-
-
84910040795
-
The investigational Aurora a kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin
-
Zullo K, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto PL, et al. The investigational Aurora a kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin. American Society of Hematology Annual Meeting; 2014. Abstract nr 7319.
-
American Society of Hematology Annual Meeting; 2014
-
-
Zullo, K.1
Guo, Y.2
Cooke, L.3
Jirau-Serrano, X.4
Mangone, M.5
Scotto, P.L.6
|